Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New rapid test could help ICU doctors pick the right antibiotic faster

NCT ID NCT03711331

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a rapid test called Unyvero could help doctors choose the right antibiotic sooner for patients with pneumonia who are on breathing machines in the ICU. The test looks for bacteria and their resistance genes in just a few hours, compared to standard lab cultures that take days. Researchers compared patients whose treatment was guided by the rapid test to those receiving standard care, to see if more patients got targeted antibiotics within 24 hours.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Unyvero multiplex PCR test (diagnostic test)
What this could lead to
If successful, this rapid test could help doctors choose the right antibiotic sooner for pneumonia patients on ventilators, reducing unnecessary broad-spectrum antibiotic use.
What could go wrong
This is a completed study with 161 patients, but the test may not always match traditional culture results, and faster treatment may not always improve outcomes. Results need confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

161 people

The number who actually took part.

Started

Jun 2020

Finished

Sep 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients hospitalized in the ICU * suspected with VAP or HAP requiring MV Exclusion Criteria: * Severe immunodeficiency * Moribund patients (SAPS II \> 90)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hospital-acquired pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial pneumonia Healthcare-Associated Pneumonia nosocomial infection Pneumonia, Ventilator-Associated

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pneumonia - bacterial Pneumonia, ventilator-associated

Contacts and locations

Locations

  • CHU Lille

    Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.